Nuhou Hui

Ua hōʻike ʻia kahi haʻawina haʻahaʻa honua i ka kūleʻa lōʻihi o ka CD19 CAR T-cell therapy i ka mālama ʻana i nā maʻi me ka relapsed/refractory acute lymphoblastic leukemia (ALL) ma hope o ka allogeneic hematopoietic stem cell transplantation, e hāʻawi ana i ka manaʻolana hou i ka hematology.

Aia ʻo Bioocus ma mua o ka hoʻomohala ʻana i nā lāʻau lapaʻau CAR-T. ʻO ka paʻi hou ʻana e Kauka Chunrong Tong a me kāna hui ma ka Halemai Lu Daopei e hōʻike ana i nā holomua koʻikoʻi a me nā pilikia i ka hoʻohana ʻana i nā lāʻau lapaʻau CD19 CAR-T o ka lua o ka hanauna i nā maʻi pediatric, e hōʻike ana i ka manaʻo o Bioocus i ka mālama ʻana i ka maʻi kanesa hou.

Hōʻike ka haʻawina haʻahaʻa honua i ka maikaʻi kupaianaha o ka lāʻau cell CAR-T i ka mālama ʻana i ka B-cell Acute Lymphoblastic Leukemia (B-ALL). ʻO ka noiʻi, e pili ana i ka hui pū ʻana me BIOOCUS a me Lu Daopei Hospital, hōʻike i nā holomua koʻikoʻi, e hoʻokumu ana i ka lāʻau lapaʻau ma ke ʻano he koho koʻikoʻi.

ʻO nā mea noiʻi mai ka Halemai ʻo Lu Daopei a me nā hoa hana o ka honua e ʻimi i nā lāʻau lapaʻau CAR-T ʻokiʻoki, e hāʻawi ana i ka manaolana no nā poʻe maʻi me nā maʻi maʻi B cell. Hōʻike kēia haʻawina i nā holomua i ka hoʻolālā a me ka noi ʻana, e hōʻike ana i nā hopena hoʻohiki a me ka hiki no nā mea hou e hiki mai ana.

Hōʻike nā haʻawina hoʻomaʻamaʻa hou i ka 4-1BB-based CD19 CAR-T cell e hōʻike ana i ka maikaʻi antitumor efficacy i hoʻohālikelike ʻia me CD28-based cell CAR-T i ka mālama ʻana i ka maʻi leukemia lymphoblastic a me refractory B cell acute lymphoblastic (r/r B-ALL).

Ua hōʻike ʻia kahi noiʻi hou ma ka Halemai Lu Daopei i ka maikaʻi kiʻekiʻe a me ka palekana o ka CD19 CAR-T cell therapy haʻahaʻa i ka mālama ʻana i nā maʻi refractory a i ʻole relapsed B acute lymphoblastic leukemia (B-ALL). ʻO ka noiʻi, kahi i loaʻa i nā maʻi maʻi 51, hōʻike i kahi helu kala kala piha me nā hopena ʻaoʻao liʻiliʻi.

Ua hoʻolaha ka Halemai ʻo Lu Daopei a me Hebei Senlang Biotechnology i nā ʻike hoʻohiki mai kā lākou noiʻi hou e pili ana i ka palekana a me ka pono o ka lāʻau CAR-T no ka maʻi maʻi B cell acute. Hōʻike kēia hui i ka hiki o nā hoʻolālā cell CAR-T hou e hoʻomaikaʻi i nā hopena maʻi.

Ua hōʻike ʻia kahi noiʻi hou i alakaʻi ʻia e Kauka Zhi-tao Ying mai ka Halemai maʻi maʻi maʻi o Peking University i ka palekana a me ka pono o ka IM19 CAR-T cell therapy i ka mālama ʻana i nā maʻi maʻi hematologic B-cell. Paʻi ʻia ma kaKa Nupepa Pake o na Laau Laau Hou, ua hōʻike ka haʻawina i ka 11 o nā maʻi 12 i loaʻa i ke kala piha me ka ʻole o nā hopena koʻikoʻi, e hōʻike ana i ka hiki o IM19 ma ke ʻano he koho lapaʻau hoʻohiki no nā poʻe maʻi me nā koho liʻiliʻi.

Ua mālama maikaʻi ʻia ka 2024 Annual Training for Clinical Blood Management and Transfusion Technology ma Sanhe City ma ka Halemai ʻo Yanda Ludaopei. Ke manaʻo nei kēia hanana e hoʻomaikaʻi i ka mālama koko a me ka palekana transfusion ma o nā kau hoʻomaʻamaʻa piha i hele ʻia e nā ʻoihana mālama ola 100 mai nā ʻoihana olakino like ʻole.

ʻO ka hōʻoia ʻana i kahi ʻike lapaʻau palekana a ʻoluʻolu no nā poʻe maʻi leukemia e pili ana i ka mālama pono i kēlā me kēia lā, me ka hoʻomaʻemaʻe kaiapuni, ka hoʻomaʻemaʻe pilikino, ka meaʻai, a me ka hoʻoikaika kino. Hāʻawi kēia alakaʻi i nā ʻōlelo aʻoaʻo koʻikoʻi no ka mālama pono i kēlā me kēia lā e kākoʻo i ka hoʻōla.

Hōʻike ʻia kahi noiʻi hou i ka pono a me ka palekana o NS7CAR-T cell therapy i ka mālama ʻana a i ʻole refractory T-cell acute lymphoblastic leukemia (R/R T-ALL) a me T-cell lymphoblastic lymphoma (R/R T-LBL). Hāʻawi kēia lāʻau lapaʻau i ka manaʻolana hou no nā poʻe maʻi me kēia mau ʻano maʻi maʻi ʻino.

Hoʻonohonoho ʻia ka 12th Annual Lu Daopei Hematology Forum ma ʻAukake 23-24, 2024, ma ka Beijing International Convention Center. E hui pū me mākou no nā kūkākūkā ʻike a me nā holomua hou i ka hematology.